Skip to main content

Enovis Corporation

corporate_fare Company Profile

Enovis Corporation

ENOV·NYSE·Industrials·CIK 0001420800

Enovis Corporation is a medical technology company that develops, manufactures, and distributes clinically differentiated solutions designed to improve patient outcomes and transform workflows. The company provides high-quality medical devices across a broad range of products used for reconstructive surgery, rehabilitation, pain management, and physical therapy. Enovis's products address the entire patient care continuum, from injury prevention to rehabilitation following surgery, injury, or degenerative disease, helping individuals regain or maintain natural motion. The company utilizes its Enovis Growth Excellence (EGX) business system, which is a set of tools, processes, and culture, to continuously improve patient outcomes and drive growth. During the year ended December 31, 2025, Enovis completed four acquisitions within its Reconstructive segment and three acquisitions within its Prevention & Recovery segment. These small acquisitions added complementary prevention & recovery product offerings, expanded distribution partners for the company's surgical implant products in Europe, and introduced a complementary surgical product technology. EGX is integral to Enovis's operations, incorporating its values and driving behaviors through comprehensive tools and repeatable processes used for continuous improvement and value creation.

Enovis Corporation (NYSE:ENOV) is a publicly traded company in the Industrials sector. Wiseek monitors ENOV SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Shareholders Approve Incentive Plan with 3.65M New Shares, Higher Director Pay Limits
  • Enovis Reports Strong Q1 Financial Turnaround, Significantly Reduces Net Loss
  • Enovis Reports Strong Q1 Results, Beats EPS Estimates, Reaffirms Full-Year Guidance
  • Enovis Exceeds Q1 EPS and Sales Estimates, Offers FY Outlook
  • Enovis Seeks Shareholder Approval for 3.65M New Shares in Omnibus Incentive Plan

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.25B
Net Income
-$1.18B
Diluted EPS
-$20.75
Op. Cash Flow
$217.29M
Free Cash Flow
$19.92M
Gross Profit
$1.35B
Operating Income
-$1.12B
Cash & Equivalents
$36.39M
Total Debt
$1.3B
Debt / Equity
0.87×
Net Margin
-52.7%
Shares Outstanding
57.19M sh
Source: 10-K · filed 2026-02-26 · accession 0001420800-26-000012
Browse all tickers starting with E →
$21.8
52-week range · as of 2026-05-19 $21 – $36.82
Market cap
$1.25B
Volume
907.7K (0.8× avg)
3-mo avg 1.2M
Live data · 2026-06-14 03:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ENOV - Latest Insights

ENOV
May 19, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.76
Real-time Price: $21.80 info
Change: -$3.96 (-15%) info
Market Cap: $1.255B info
ENOV
May 07, 2026, 6:33 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.45
Real-time Price: $21.80 info
Change: -$3.65 (-14%) info
Market Cap: $1.255B info
ENOV
May 07, 2026, 6:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.45
Real-time Price: $21.80 info
Change: -$3.65 (-14%) info
Market Cap: $1.255B info
ENOV
May 07, 2026, 6:01 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $25.45
Real-time Price: $21.80 info
Change: -$3.65 (-14%) info
Market Cap: $1.255B info
ENOV
Apr 06, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $22.76
Real-time Price: $21.80 info
Change: -$0.960 (-4%) info
Market Cap: $1.255B info
ENOV
Feb 26, 2026, 6:22 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $22.32
Real-time Price: $21.80 info
Change: -$0.520 (-2%) info
Market Cap: $1.255B info
ENOV
Jan 12, 2026, 6:45 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.68
Real-time Price: $21.80 info
Change: -$7.88 (-27%) info
Market Cap: $1.255B info